Our findings here, coupled with the studies investigating FPR small agonists in myocardial infarction (Garcia et al, 2021; Qin et al, 2017), identify cardiac syndromes as ideal disease targets for this family of pharmacologically active compounds. The gene discussed is FPR1; the disease is myocardial infarction.